Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07134738) titled 'Dimolegin(R) (60 mg) for Patients With Moderate COVID-19: A Non-Interventional Study' on Aug. 8.

Study Type: Observational

Primary Sponsor: Avexima Diol LLC

Condition: COVID-19

Intervention: Drug: Dimolegin

Recruitment Status: Not recruiting

Date of First Enrollment: June 7, 2024

Target Sample Size: 184

Countries of Recruitment: Russian Federation

To know more, visit https://clinicaltrials.gov/ct2/show/NCT07134738

Published by HT Digital Content Services with permission from Health Daily Digest....